Kura Oncology (NASDAQ:KURA) Insider Francis Burrows Sells 20,726 Shares of Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Francis Burrows sold 20,726 shares of the stock in a transaction that occurred on Thursday, September 24th. The stock was sold at an average price of $10.83, for a total transaction of $224,462.58. Following the completion of the sale, the insider directly owned 42,327 shares of the company’s stock, valued at $458,401.41. This trade represents a 32.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kura Oncology Stock Down 0.9%

Shares of NASDAQ KURA traded down $0.10 during mid-day trading on Friday, reaching $10.76. The company had a trading volume of 1,226,675 shares, compared to its average volume of 1,672,906. The stock has a market capitalization of $957.21 million, a PE ratio of -3.19 and a beta of 0.44. Kura Oncology, Inc. has a twelve month low of $7.36 and a twelve month high of $13.90. The company has a debt-to-equity ratio of 0.12, a quick ratio of 4.71 and a current ratio of 4.73. The stock’s 50 day moving average is $11.22 and its 200-day moving average is $10.13.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative return on equity of 207.18% and a negative net margin of 384.30%.The company had revenue of $20.87 million during the quarter, compared to the consensus estimate of $20.16 million. As a group, equities analysts anticipate that Kura Oncology, Inc. will post -3.25 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on KURA shares. Oppenheimer set a $24.00 target price on shares of Kura Oncology in a research note on Thursday, May 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Thursday, June 4th. Raymond James Financial set a $24.00 price target on shares of Kura Oncology in a research report on Monday, August 24th. Jefferies Financial Group set a $24.00 price target on Kura Oncology in a report on Thursday, May 28th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of KURA. BlackRock Inc. acquired a new stake in shares of Kura Oncology during the second quarter worth $115,286,000. Bank of America Corp DE acquired a new stake in shares of Kura Oncology in the second quarter valued at approximately $12,735,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Kura Oncology during the 2nd quarter worth about $10,927,000. Fisher Asset Management LLC acquired a new position in shares of Kura Oncology during the 4th quarter worth about $4,904,000. Finally, Man Group plc bought a new position in shares of Kura Oncology in the 2nd quarter valued at about $4,749,000.

About Kura Oncology

Kura Oncology, Inc is a biopharmaceutical company focused on developing precision medicines for the treatment of cancer. The company’s research programs target specific genetic and molecular abnormalities that contribute to tumor growth, with an emphasis on hematologic malignancies and selected solid tumors.

Kura’s leading program has been ziftomenib, an oral, selective menin inhibitor being developed for genetically defined forms of acute myeloid leukemia, including cancers with NPM1 mutations or certain KMT2A rearrangements.